顶部联系方式

Time of issue:2019-09-22 00:00:00
EN
SEARCH
Confirm
Cancel

HUAPONT PHARM

NEWS

Effect of Ruxolitinib phosphate on COVID-19
Check category

Effect of Ruxolitinib phosphate on COVID-19

  • Categories:2020
  • Author:
  • Origin:
  • Time of issue:2020-06-22 17:30
  • Views:0

【Summary】April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.

Effect of Ruxolitinib phosphate on COVID-19

【Summary】April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.

  • Categories:2020
  • Author:
  • Origin:
  • Time of issue:2020-06-22 17:30
  • Views:0
Information

April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.

Scan the QR code to read on your phone

Bangbang Bird

QUICK LINKS

Quick Links

Time of issue:2020-05-28 00:00:00

CONTACT INFO

Contact Info

Time of issue:2020-05-28 00:00:00

TEL: +86-23-67886927

TEL: +86-23-67886928

EMAIL: api@huapont.cn

ADD.: No.69 Xingguang Avenue, Renhe Town, Yubei District,Chongqing, China 401121

FEEDBACK

留言应用名称:
feedback
Description:
验证码

地址版权

Time of issue:2019-09-22 00:00:00

© 2020 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved. Powered by: www.300.cn 渝ICP备05003324号

手机版地址版权

Time of issue:2019-09-22 00:00:00

© 2020 Chongqing Huapont Pharmaceutical Co., Ltd.

Powered by: www.300.cn 渝ICP备05003324号